XPhyto Therapeutics Corp. XPHYF Archives - Page 3 of 5

ThursdayMay 06, 2021 1:00 pm

QualityStocksNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Featured on Gamechangers LIVE

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) was featured in a recent episode of Gamechangers LIVE, a podcast series that shines a spotlight on individuals who are gamechangers in their fields and shares perspective on their journeys, mindsets, struggles and successes in an effort to inspire and inform listeners. XPhyto Therapeutics’ CEO and Director, Hugh Rogers, joined the broadcast, hosted by Executive Coach and Speaker Sergio Tigera, to discuss the company’s various lines of business, including its work to scale industrial production of pharmaceutical-grade psychedelics. “The psychedelic space is really exciting. This is absolutely the cutting edge of mental…

TuesdayMay 04, 2021 2:28 pm

XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Inks Distribution Agreement for Rapid COVID-19 Test Kits; Expands Commercial Leadership Team in Anticipation of Strong, Sustainable Sales

XPhyto Therapeutics Corp. recently announced it has entered into a distribution, storage and logistics agreement with a German distributor with an established network throughout Germany Germany holds promise due to regulations requiring mandatory weekly testing for its citizens; this has the possibility of ramping up sales Anticipating the increase in sales and distribution, XPhyto expanded its commercial leadership team by bringing on board Mr. Wolfgang Probst and Mr. Manfred Buchberger Mr. Probst will be the company’s Chief Operations Officer (“COO”), while Mr. Buchberger will be the Head of Corporate Development at wholly owned subsidiary XP Diagnostics GmbH The approvals XPhyto…

MondayMay 03, 2021 3:20 pm

QualityStocksNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Eyes Significant Market Opportunity

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience technology accelerator, raised eyebrows when it announced that XPhyto Laboratories Inc., its Alberta subsidiary, added mescaline production to its psychedelic medicine development programs earlier this year (https://ibn.fm/cHwJi). Mescaline has begun attracting legislative attention, much like was the case with cannabis, which gained widening legalization as state after state approved varied uses of hemp and cannabis within their political boundaries. Recently, California Senator Scott Wiener introduced a bill that would decriminalize select hallucinogenics, including mescaline, in part due to research from top medical universities indicating that such substances can have significant benefits…

WednesdayApr 28, 2021 10:11 am

QualityStocksNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Pursues Market Access in Israel for ‘Covid-ID Lab’

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) today announced that it has delivered 2,000 of its rapid 25-minute PCR tests ("Covid-ID Lab") to an established medical distributor in Israel for clinical evaluation of Covid-ID Lab for the purpose of commercial regulatory approval and potential product distribution. According to the update, the Israeli distributor markets and distributes a range of medical products and diagnostics in Israel and surrounding Middle Eastern countries. Its customers include government and private institutions such as hospitals, pharmacies and a broad range of health care providers. "We are excited by the opportunity to expand potential distribution…

WednesdayApr 21, 2021 3:38 pm

QualityStocksNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Achieves Critical Step Toward Commercial Sales of ‘Covid-ID Lab’

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) today announced its entry into an agreement with an established German pharmaceutical wholesaler and service provider for the distribution, storage and logistics of XPhyto's diagnostic products in Germany. According to the update, the agreement secures XPhyto a full-service distribution partner for its 25-minute SARS-CoV-2 (COVID-19) RT-PCR test system ("Covid-ID Lab"). "With this agreement, we have secured a strong partner with an established medical distribution network throughout Germany. This is an exciting and critical step towards commercial sales of Covid-ID Lab," said Hugh Rogers, CEO and director of XPhyto. "The company's commercialization strategy…

TuesdayApr 20, 2021 9:47 am

QualityStocksNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Announces Appointment of New Global Positions

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities, has appointed two new positions at XP Diagnostics GmbH, its wholly owned German subsidiary. Wolfgang Probst will serve as the company’s new chief operations officer and Manfred Buchberger will be the new head of corporate development. An experienced management and finance consultant with impressive exposure to mergers and acquisitions, corporate re-organizations, and divestitures, Probst has a proven track record of leadership, strategic planning and organizational restructuring. In his new position, he will be responsible for managing the company's…

FridayApr 16, 2021 12:14 pm

Largely Untapped Market for Hallucinogenic Draws Attention of Researchers at XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT)

XPhyto Therapeutics Corp., a life sciences technology accelerator, is looking for ways to turn promising psychedelics into therapeutic pharmaceutical drugs, and recently added mescaline to its study profile Mescaline is illegal under U.S. federal law, but some state-centric efforts to legalize or decriminalize the hallucinogenic have launched in a manner similar to the populace effort that produced a wave of cannabis product legalization Mescaline has historically defied predictable outcomes by researchers, but advocates cite it as a means of successfully treating some mental health and substance abuse disorders A number of psychedelics production stocks saw huge gains during the past…

ThursdayApr 15, 2021 11:38 am

QualityStocksNewsBreaks – XPhyto Therapeutics Corp.’s (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) ‘Covid-ID Lab’ Combines Speed of Rapid Screening with Accuracy of PCR Diagnostic

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience technology accelerator, is set to launch a solution for improving detection of the virus responsible for the worldwide pandemic. The company recently announced European regulatory approval of its point-of-care SARS-CoV-2 (COVID-19) RT-PCR test system. Known as “Covid-ID Lab,” the system is a commercial in-vitro diagnostic device (CE-IVD) designed to help industry professionals and government agencies screen for the virus. XPhyto’s exclusive German diagnostics partner, 3a-diagnostics GmbH, developed Covid-ID Lab to provide rapid, accurate and portable testing capabilities, granting it marketability as a product with increased convenience and decreased operating costs.…

MondayApr 12, 2021 1:00 pm

XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Files First Order for Rapid COVID Test Kits Amid European Regulatory Approval

Bioscience technology accelerator XPhyto Therapeutics Corp. recently announced it had placed its first order for its Covid-ID Lab rapid, portable virus test from its German development partner XPhyto received approval for the test kit last month from European regulators with oversight of in vitro diagnostic device (CE-IVD) use certification and the internationally agreed-on ISO 13485 medical product quality standards The Covid-ID Lab is designed to help beleaguered industries and government regulators quickly screen for the COVID-19 virus at point-of-care sites, and the company expects to begin sales and distribution in April XPhyto has just completed a rebranding effort that includes…

ThursdayApr 08, 2021 2:35 pm

XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Commercialization Team Set to Launch Rapid POC COVID Test Solution

Bioscience technology accelerator XPhyto Therapeutics Corp. is working with development partner 3a-diagnostics GmbH to roll out its pandemic-related virus diagnostic tool for the European market planned in April The test solution, dubbed “Covid-ID Lab,” received European regulatory approval last month XPhyto’s product is designed to be portable and rapid in its response time to help decrease testing operation costs and increase convenience of use News reports about the COVID-19 pandemic reflect a growing optimism that vaccine, mask and distancing protocols may be helping to drive down infection rates, although the reports note the virus continues to have a deadly effect…

Site Search

Company Search

Tag: XPhyto Therapeutics Corp. XPHYF